Introduction: Hearing loss is a common chronic problem which can be effectively managed with hearing devices. At present, only a limited number of people with hearing loss use hearing aids (HAs) and cochlear implants (CIs) to improve hearing and sound quality and enhance quality of life. Clinical equipoise, by which we mean healthcare professional uncertainty about which treatment options are the most efficacious due to the lack of evidence-based information, can lead to inconsistent and poorly informed referral processes for hearing devices.A randomised controlled trial (RCT) that offers high-quality, generalisable information is needed to clarify which hearing device (HA or CI) is more suitable for different degrees of hearing loss and for which kinds of patients. Qualitative research can improve this RCT, by gathering the information on patient and provider perspectives, attitudes and values, which can inform design, conduct and information dissemination, either during preparatory stages of an intervention, or as a fully integrated methodology. The Comparison of Outcomes with hearing Aids and Cochlear implants in adults with moderately severe-to-profound bilateral sensorineural Hearing loss (COACH) study is being planned as an RCT with a qualitative arm (the qualitative COACH study, q-COACH), acting as a pretrial intervention examining views of HAs, CIs, equipoise and the impetus for an RCT of this nature.

Methods And Analysis: The q-COACH study involves semistructured interviews and a demographic questionnaire which will be collected from four participant cohorts: General Practitioners (GPs) and Ear, Nose and Throat Surgeons (ENTs); audiologists; adult HA users and their support networks. Data will be analysed thematically and through descriptive statistics.

Ethics And Dissemination: Macquarie University Human Research Ethics Committee, Australia, granted ethical approval (no. 5201833514848). Peer-reviewed journal articles, research conferences and a final report will present study findings.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738701PMC
http://dx.doi.org/10.1136/bmjopen-2019-030100DOI Listing

Publication Analysis

Top Keywords

hearing loss
16
hearing
11
clinical equipoise
8
hearing devices
8
qualitative coach
8
q-coach study
8
randomised controlled
8
controlled trial
8
hearing aids
8
aids cochlear
8

Similar Publications

In this report, we describe the first reported case of an oropharyngeal accessory tragus in a 20-year-old female presenting with moderate to severe left-sided conductive hearing loss. This case shares rare developmental anomalies to consider when diagnosing oropharyngeal masses that highlight the intricate embryological development of the head and neck region.

View Article and Find Full Text PDF

Purpose: Benzodiazepine receptor agonists (BZRAs), including benzodiazepines (BZDs) and Z drugs, are widely prescribed for anxiety and sleep. Therefore, issues of tolerance, dependence and adverse effects are of concern. Recent studies suggested a potential link between BZRAs and hearing problems.

View Article and Find Full Text PDF

Cochlear implantation (CI) is currently recognized as the most effective treatment for severe to profound sensorineural deafness and is considered one of the most successful neural prostheses. Since its inception in 1961, cochlear implantation has expanded its range of applications to encompass younger newborns, older people, and individuals with unilateral hearing loss. In addition, it has improved its surgical methods to minimize the occurrence of complications.

View Article and Find Full Text PDF

Objectives: The movement towards personalization of cochlear implantation has continued to generate interest about variabilities in cochlear size. In a recent meta-analysis, Atalay et al. (2022) examined organ of corti length, cochlear lateral wall, and "A" value and found that most covariates, other than congenital sensorineural hearing loss, did not impact cochlear size via these measurements.

View Article and Find Full Text PDF

Thiamine responsive megaloblastic anemia (TRMA), also known as Roger's syndrome, is an exceptionally rare autosomal recessive disorder stemming from mutations in the SLC19A2 gene responsible for encoding a thiamine carrier protein. This syndrome manifests as the classic triad of megaloblastic anemia, sensorineural hearing loss, and diabetes mellitus. Here, we present the case of a one-and-a-half-year-old male infant born to non-consanguineous parents in India, a region where TRMA cases are seldom reported.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!